Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Editorial: Insights Into Biomarkers, Cytokines, and Chemokines in Skin Cancer

Our current Research Topic highlights the complexity of the relationship between the skin, immune system and skin cancer

Research

Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors

Early changes in cell morphology upon treatments are a strong indication that the inhibitor is directly targeting tubulin

Research

Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103− and XCR1+CD103+ dendritic cells

This report provides new insight into the functional specialization within the broad network of dendritic cells that are responsible for skin immunosurveillance

Research

T cells recognizing a 11mer influenza peptide complexed to H-2D b show promiscuity for peptide length

T-cell repertoire is selected according to self peptide-MHC (major histocompatibility complex) complexes in the thymus.

Research

Renal Masses in Childhood: An Australian Perspective

Childhood renal masses comprise a heterogeneous group of conditions that have a wide range of presentations. This review outlines an approach to the diagnostic work-up of childhood renal masses and discusses the most common presentations and treatments. Renal tumours make up 5% of childhood cancer in Australia, with Wilms tumour being the most common under age 10 years.

Research

Prostaglandin E2 imprints a long-lasting effect on dendritic cell progenitors in the bone marrow

Injection of BM-differentiated DCs from nonchimeric mice restored the reduced immune responses of PGE2-chimeric mice.

Research

Timing of excision after a non-severe burn has a significant impact on the subsequent immune response in a murine model

Early excision of the wound, during the phase of immune down-regulation initiated by the burn, maintains an innate and adaptive immune cell response

Research

Making a Killer: Selecting the Optimal Natural Killer Cells for Improved Immunotherapies

Over the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching.